LINE in the 13F filings
Lineage Cell Theraputics In · CUSIP 53566V106
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 23 Jan 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 7 listed it in both
- Shares listed
- 18,069,148
- combined, among listed positions
- Reported value
- $632m
- combined, at the quarter end
Among the 92 comparable managers: 13 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -546,257.
Managers listing LINE in Q4 2025
22 of 22 holders
Largest increases and reductions, by shares
Increases
- D1 Capital Partners LPexisting position · 7,402,229 shares now+1,220,335
- AQR Capital Management LLCexisting position · 1,330,439 shares now+1,149,686
- Millennium Management LLCnew position · 640,587 shares now+640,587
- Moore Capital Management LPnew position · 407,412 shares now+407,412
- Jane Street Group LLCnew position · 273,749 shares now+273,749
Reductions
- Janus Henderson Group Ltdexisting position · 27,478 shares now-3,710,533
- Capital Research Global Investorsexisting position · 2,790,338 shares now-362,611
- Schonfeld Strategic Advisors LLCexisting position · 24,517 shares now-243,142
- Baillie Gifford & Coexisting position · 2,786,283 shares now-167,958
- Artisan Partners LPexisting position · 294,920 shares now-52,405
New positions and exits
New (5)
Exited (3)
- Squarepoint Ops LLCwas $2.4m
- Balyasny Asset Management LLCwas $532k
- Verition Fund Management LLCwas $249k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2024 | 16 | $1.5bn | 16 | 0 |
| Q4 2024 | 12 | $1.1bn | 9 | 7 |
| Q1 2025 | 9 | $1.3bn | 6 | 3 |
| Q2 2025 | 11 | $1.0bn | 8 | 3 |
| Q3 2025 | 7 | $646m | 4 | 4 |
| Q4 2025 | 6 | $481m | 13 | 12 |
| Q1 2026 | 4 | $341m | 13 | 12 |
| Q2 2026 | 4 | $513m | 9 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LINE and WELL →LINE and EQIX →LINE and PLD →Choose a stock to compare with LINE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LINE, latest filings →Back to the 13F Explorer →